Bobylev et al. have published clinical data on the use of the "Cell-free human pulmonary valve, Espoir PV" in April 2022. The 5-year data from the prospective ESPOIR study (121 patients, 637 follow-up years) and the 15-year data from the ESPOIR registry (361 patients, 2011 follow-up years) show excellent clinical results and a low rate of adverse events. Compared to conventional homografts, a statistically significantly better freedom from explantation could be demonstrated. You can find the original article in our Media Center.